(Reuters) - U.S. regulators said on Wednesday that Mylan NV's EpiPen products are in shortage due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy ...

Mylan and federal investigators Thursday finalized a $465 million settlement of charges the drugmaker overcharged the government for the injection allergy medication EpiPen. Resolving an issue that ...

(Reuters) - Mylan NV on Friday said it will pay $465 million to settle questions of whether it underpaid U.S. government healthcare programs by misclassifying its EpiPen emergency allergy treatment, ...

Mylan’s $465 million proposed settlement with CMS may not cover the amount of money it allegedly saved by improperly classifying EpiPens as a generic drug, according to research published Monday in ...

Outraged Republican and Democratic lawmakers on Wednesday grilled the head of pharmaceutical company Mylan about the significant cost increase of its life-saving EpiPens and the profits for a company ...

When Mylan CEO Heather Bresch testified before the House Oversight Committee Sept. 21, she told lawmakers the company makes $100 in profit off a two-pack of EpiPens listed at $608. However, Ms. Bresch ...

Mylan is bulking up programs that help patients pay for its EpiPen emergency allergy treatment after weathering heated criticism about an average cost that has climbed more than 600 percent over the ...

Mylan was slapped Monday with a class-action racketeering lawsuit that claims the company overcharged patients as part of an illegal scheme to secure sales, CNBC reported. The suit, filed in U.S.